Prenetics Global (PRE) Registration Filing summary

Company overview and business model

• Focuses on consumer health, longevity, and preventive wellness, leveraging scientific expertise and digital asset innovation.

• Operates premium supplement brand IM8 Health, genetic testing brand CircleDNA, and holds a 35% stake in early cancer detection firm Insighta.

• Recently divested ACT Genomics to streamline operations and focus on high-margin consumer health.

• Strategic transformation includes integrating Bitcoin as a treasury asset and exploring blockchain applications in healthcare.

Financial performance and metrics

• IM8 Health achieved over 60,000 customers in 31 countries and a $60M ARR run-rate within six months of launch, targeting $100M ARR by year-end.

• As of June 30, 2025, consolidated current assets (excluding ACT Genomics) were $44M, with $17M in cash and $20M in Bitcoin classified as non-current intangible assets.

• ACT Genomics divestment generated $46M in gross proceeds, enhancing financial flexibility.

Use of proceeds and capital allocation

• Net proceeds from securities sales may be used to acquire Bitcoin and other major cryptocurrencies, and for general corporate purposes.

• Board-approved strategy to allocate up to 80% of available cash (excluding operational needs) to Bitcoin, maintaining at least 24 months of operational liquidity.

• May explore additional alpha-generating strategies with Bitcoin after establishing core treasury position.